For example, QDs can be developed to target and label proteins such as prostate-specific antigen (PSA) (Shi et al., 2008) or HER2 receptors (Chen et al., 2009; Al-Ani et al., 2021), which are overexpressed in certain types of cancer. This evidence concerns the gene KLK3 and cancer.